Taisho Pharmaceutical Co., Ltd.

Michio Yamagishi

Sadafumi Omura

Taku Mizutani

Haruo Seto

Noboru Otake

Kazutoshi Mizoue

Akira Kawashima

Hiroshi Hara

Shigeo Tanaka

Hideyo Yamaguchi

Kimiko Sugita

Toshi Akashi

Hideki Kohita

Kiyotaka Obata

Kazuo Numata

Naoharu Watanabe

Antifungal agent

Method for the treatment of systemic mycosis of mammals comprises administering (S)-2-amino-5-hydroxy-4-oxopentanoicacid in a therapeutically effective amount to said mammals suffering from mycosis, typically candidosis.

Method for the treatment of systemic mycosis

A novel compound of the formula ##STR1## and the salts thereof, derived from dianemycin, are useful as antiprotozoal and antibacterial agents.

Novel dianemycin derivative

The novel antibiotics represented by the formula ##STR1## wherein either (a) R.sup.1 is hydroxy and R.sup.2 is hydrogen, or (b) R.sup.1 is methoxy and R.sup.2 is hydroxy, and the salt thereof, are produced by the cultivation of the organism Streptomyces hygroscopicus TM-531 under aerobic conditions. They are separated from coproduced Antibiotic TM-531 as disclosed in U.S. Pat. No. 4,269,971 and from each other by chromatography on silica gel.

Antibiotics TM-531 B and TM-531 C

Antibiotic TM-531 having the formula: ##STR1## TM-531 is effective against gram-positive bacteria, plant pathogenic microorganisms and protozoa.

Antibiotic TM-531

Novel lonomycin derivatives, prepared by reacting lonomycin or its salt with an alkali or an alkali metal borohydride, show antibacterial, antiviral and antiprotozoal activity, and have decreased toxicity as compared with lonomycin.

Novel lonomycin derivatives

Growing community of inventors

Tokorozawa, Japan

Michio Yamagishi